CD19 and autoimmune thrombocytopenic purpura: Moreover, given the preliminary data’s insufficiency in SLE associated malignancies, a recent case report (57) suggests that CD19 CAR-T therapy may hold promise for SLE patients with immune thrombocytopenia (ITP).